10Sep 2023
Fort Collins Man Achieves Remarkable Remission in Hemophilia A through Groundbreaking Medication Trial

Fort Collins Man Achieves Remarkable Remission in Hemophilia A through Groundbreaking Medication Trial

In a groundbreaking development, a 36-year-old with Hemophilia A from northern Colorado participated in a Roctavian medication trial, which recently gained FDA approval. Born with Hemophilia A, Schulz had endured thousands of self-administered injections to manage the disorder's symptoms. However, the trial's single infusion gene therapy essentially cured him, eliminating the need for frequent shots and transforming his life. Schulz's positive outcome contributed to the FDA's approval of Roctavian, offering hope for those with Hemophilia A. This innovative treatment may potentially reshape the future of Hemophilia management and prevention.

  • #family health

Like

Save

Share